These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19752838)

  • 1. Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study.
    Rothschild AJ; Dunlop BW; Dunner DL; Friedman ES; Gelenberg A; Holland P; Kocsis JH; Kornstein SG; Shelton R; Trivedi MH; Zajecka JM; Goldstein C; Thase ME; Pedersen R; Keller MB
    Psychopharmacol Bull; 2009; 42(3):5-20. PubMed ID: 19752838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study.
    Kornstein SG; Pedersen RD; Holland PJ; Nemeroff CB; Rothschild AJ; Thase ME; Trivedi MH; Ninan PT; Keller MB
    J Clin Psychiatry; 2014 Jan; 75(1):62-8. PubMed ID: 24345717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study.
    Kocsis JH; Thase ME; Trivedi MH; Shelton RC; Kornstein SG; Nemeroff CB; Friedman ES; Gelenberg AJ; Dunner DL; Hirschfeld RM; Rothschild AJ; Ferguson JM; Schatzberg AF; Zajecka JM; Pedersen RD; Yan B; Ahmed S; Musgnung J; Ninan PT; Keller MB
    J Clin Psychiatry; 2007 Jul; 68(7):1014-23. PubMed ID: 17685736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond remission: rationale and design of the Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study.
    Kornstein SG
    CNS Spectr; 2006 Dec; 11(12 Suppl 15):28-34. PubMed ID: 17146416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases.
    Keller MB; Trivedi MH; Thase ME; Shelton RC; Kornstein SG; Nemeroff CB; Friedman ES; Gelenberg AJ; Kocsis JH; Dunner DL; Hirschfeld RM; Rothschild AJ; Ferguson JM; Schatzberg AF; Zajecka JM; Pedersen RD; Yan B; Ahmed S; Musgnung J; Ninan PT
    J Clin Psychiatry; 2007 Aug; 68(8):1246-56. PubMed ID: 17854250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study.
    Thase ME; Gelenberg A; Kornstein SG; Kocsis JH; Trivedi MH; Ninan P; Li T; Pedersen R; Keller M
    J Psychiatr Res; 2011 Mar; 45(3):412-20. PubMed ID: 20801464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study.
    Kornstein SG; Kocsis JH; Ahmed S; Thase M; Friedman ES; Dunlop BW; Yan B; Pedersen R; Ninan PT; Li T; Keller M
    Int Clin Psychopharmacol; 2008 Nov; 23(6):357-63. PubMed ID: 18854724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venlafaxine extended-release: a review of its use in the management of major depression.
    Wellington K; Perry CM
    CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venlafaxine versus placebo in the preventive treatment of recurrent major depression.
    Montgomery SA; Entsuah R; Hackett D; Kunz NR; Rudolph RL;
    J Clin Psychiatry; 2004 Mar; 65(3):328-36. PubMed ID: 15096071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.
    Silverstone PH; Salinas E
    J Clin Psychiatry; 2001 Jul; 62(7):523-9. PubMed ID: 11488362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo.
    Shelton C; Entsuah R; Padmanabhan SK; Vinall PE
    Int Clin Psychopharmacol; 2005 Jul; 20(4):233-8. PubMed ID: 15933485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venlafaxine extended-release for depression following spinal cord injury: a randomized clinical trial.
    Fann JR; Bombardier CH; Richards JS; Wilson CS; Heinemann AW; Warren AM; Brooks L; McCullumsmith CB; Temkin NR; Warms C; Tate DG;
    JAMA Psychiatry; 2015 Mar; 72(3):247-58. PubMed ID: 25607727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual reuptake inhibitors incur lower rates of tachyphylaxis than selective serotonin reuptake inhibitors: a retrospective study.
    Posternak MA; Zimmerman M
    J Clin Psychiatry; 2005 Jun; 66(6):705-7. PubMed ID: 15960562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression.
    Schatzberg A; Roose S
    Am J Geriatr Psychiatry; 2006 Apr; 14(4):361-70. PubMed ID: 16582045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder.
    Trivedi MH; Wan GJ; Mallick R; Chen J; Casciano R; Geissler EC; Panish JM
    J Clin Psychopharmacol; 2004 Oct; 24(5):497-506. PubMed ID: 15349005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases.
    Keller MB; Trivedi MH; Thase ME; Shelton RC; Kornstein SG; Nemeroff CB; Friedman ES; Gelenberg AJ; Kocsis JH; Dunner DL; Dunlop BW; Hirschfeld RM; Rothschild AJ; Ferguson JM; Schatzberg AF; Zajecka JM; Pedersen R; Yan B; Ahmed S; Schmidt M; Ninan PT
    Biol Psychiatry; 2007 Dec; 62(12):1371-9. PubMed ID: 17825800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release.
    Ferguson JM; Khan A; Mangano R; Entsuah R; Tzanis E
    J Clin Psychiatry; 2007 Jan; 68(1):58-68. PubMed ID: 17284131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic features.
    Sheehan DV; Nemeroff CB; Thase ME; Entsuah R;
    Int Clin Psychopharmacol; 2009 Mar; 24(2):61-86. PubMed ID: 19238088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder.
    Kroenke K; Messina N; Benattia I; Graepel J; Musgnung J
    J Clin Psychiatry; 2006 Jan; 67(1):72-80. PubMed ID: 16426091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials.
    Emslie GJ; Findling RL; Yeung PP; Kunz NR; Li Y
    J Am Acad Child Adolesc Psychiatry; 2007 Apr; 46(4):479-488. PubMed ID: 17420682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.